The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. NOXXON disavows any obligation to update the information contained in such press releases after the date of their issuance.
Filter: NOX-A12 (olaptesed) | NOX-E36 (emapticap) | all
| Date | Title | Download | ||
| 2021, February 15 06:00 p.m. | NOXXON enrolls first patient in the high dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer |  |  |  |
| 2021, February 08 06:00 p.m. | NOXXON appoints leading pancreatic cancer experts to Scientific Advisory Board | | | |
| 2021, February 01 06:00 p.m. | NOXXON appoints experienced cancer drug developer Dr. Jose Saro as chair of Scientific Advisory Board | | | |
| 2021, January 26 08:00 a.m. | NOXXON announces capital increase of Euro 6.4 million by private placement to further develop its business | | | |
| 2021, January 19 08:00 a.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2020, December 29 08:00 p.m. | NOXXON announces initiation of NOX-A12 manufacturing for future clinical studies | | | |
| 2020, November 09 08:00 a.m. | NOXXON announces that Data Safety Monitoring Board validates further NOX-A12 dose escalation in Phase 1/2 brain cancer study | | | |
| 2020, October 29 08:00 a.m. | NOXXON publishes interim 2020 results | | | |
| 2020, October 28 08:00 a.m. | NOXXON announces completion of 6-month therapy for low-dose cohort in Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2020, October 20 08:00 a.m. | NOXXON announces three additional clinical centers to recruit patients for NOX-A12 brain cancer trial | | | |
| 2020, October 14 07:00 p.m. | NOXXON secures expanded capacity and improved conversion conditions for convertible bonds from Atlas | | | |
| 2020, October 14 08:00 a.m. | NOXXON announces successful completion of patient recruitment for second dose cohort in phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2020, September 17 09:00 a.m. | NOXXON presents final clinical data from phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the ESMO virtual congress 2020 | | | |
| 2020, August 12 6:00 p.m. | NOXXON to present final clinical data from the NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the ESMO virtual congress 2020 | | | |
| 2020, July 24 8:00 a.m. | NOXXON announces first brain cancer patient from second dose cohort reaches 4 weeks of treatment with NOX-A12 combined with radiotherapy | | | |
| 2020, July 13 6:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2020, July 02 8:00 a.m. | NOXXON announces appointment of Oscar Izeboud to the supervisory board and provides results of the annual general shareholders meeting | | | |
| 2020, June 30 6:00 p.m. | NOXXON enrolls first patient in the second dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer | | | |
| 2020, June 16 6:00 p.m. | NOXXON announces capital increase of Euro 1.3 million by private placement to further develop its business | | | |
| 2020, June 12 6:00 p.m. | NOXXON announces issuance of tranches of Convertible Bonds under financing agreement with Atlas | | | |
| 2020, May 29 6:00 p.m. | NOXXON announces convocation of the hybrid annual general meeting of shareholders | | | |
| 2020, May 08 9:00 p.m. | NOXXON announces capital increase of EUR 5.5 million by private placement to further develop its business | | | |
| 2020, May 06 8:00 p.m. | NOXXON announces issuance of a tranche of Convertible Bonds under financing agreement with Atlas | | | |
| 2020, April 27 6:00 p.m. | NOXXON presents latest clinical data from the Phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020 | | | |
| 2020, April 24 8:00 a.m. | NOXXON announces that Data Safety Monitoring Board validates NOX-A12 dose escalation in Phase 1/2 brain cancer study | | | |
| 2020, April 23 8:00 a.m. | NOXXON secures financing of up to 14.2 million Euro through convertible bonds from Atlas | | | |
| 2020, April 22 8:00 a.m. | NOXXON Pharma N.V. reports 2019 financial results | | | |
| 2020, April 20 7:00 p.m. | NOXXON announces complete conversion of Acuitas warrants | | | |
| 2020, April 14 6:00 p.m. | NOXXON to present latest clinical data from the NOX-A12 / KEYTRUDA combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020 | | | |
| 2020, April 02 8:00 a.m. | NOXXON announces completion of patient recruitment for the first dose cohort in the phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2020, March 31 6:00 p.m. | NOXXON provides update on clinical trial recruitment and corporate operations during COVID-19 pandemic | | | |
| 2020, January 20 6:00 p.m. | NOXXON announces another capital increase of 0.5 million Euro through a private placement of shares | | | |
| 2020, January 16 6:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2020, January 14 8:00 a.m. | NOXXON announces a capital increase of 0.5 million Euro through a private placement of shares | | | |
| 2019, December 20 8:00 a.m. | NOXXON announces first brain cancer patient reaches 10 weeks of treatment with NOX-A12 plus radiotherapy | | | |
| 2019, October 24 6:00 p.m. | NOXXON publishes interim 2019 results | | | |
| 2019, October 16 8:00 a.m. | NOXXON enrolls first patient in the phase 1/2 clinical trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer | | | |
| 2019, September 29 12:00 p.m. | NOXXON presents latest clinical data from Phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress | | | |
| 2019, September 18 8:00 a.m. | NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the ESMO congress | | | |
| 2019, September 12 6:00 p.m. | NOXXON initiates patient recruitment for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer patients | | | |
| 2019, August 15 8:00 a.m. | NOXXON announces completion of EUR 1 million capital increase | | | |
| 2019, August 06 8:00 p.m. | NOXXON announces a capital increase of Euro 1 million through a private placement of shares without warrants | | | |
| 2019, July 22 8:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2019, July 19 8:30 p.m. | NOXXON raises amount of Euro 521 K in its rights issue | | | |
| 2019, June 27 8:00 a.m. | Results of NOXXON annual general shareholders meeting | | | |
| 2019, June 26 8:00 a.m. | NOXXON announces launch of capital increase right issue for an amount of up to Euro 3.9 M | | | |
| 2019, June 24 8:00 a.m. | NOXXON announces leading international pharma to evaluate NOX-A12 in new indication | | | |
| 2019, May 24 6:00 p.m. | NOXXON announces convocation of the annual general meeting of shareholders | | | |
| 2019, May 03 8:00 p.m. | NOXXON announces change within supervisory board | | | |
| 2019, April 12 7:00 p.m. | NOXXON Pharma N.V. reports 2018 financial results | | | |
| 2019, April 01 7:00 p.m. | NOXXON presents updated results from Phase 1/2 NOX-A12 / Keytruda combination trial at AACR 2019 | | | |
| 2019, February 28 7:00 p.m. | NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting | | | |
| 2019, February 27 6:00 p.m. | NOXXON files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer | | | |
| 2019, February 18 8:00 a.m. | NOXXON publishes a shareholder letter | | | |
| 2019, February 01 8:00 a.m. | New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer | | | |
| 2019, January 14 6:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2019, January 04 8:00 a.m. | Results of NOXXON's extra-ordinary general meeting of shareholders | | | |
| 2018, December 20 8:00 a.m. | NOXXON announces participation in the East/West CEO Forum in San Francisco, in January 2019 | | | |
| 2018, December 14 12:30 p.m. | NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients | | | |
| 2018, December 13 8:00 p.m. | NOXXON announces trading halt on Euronext Growth Paris ahead of trial data publication at the ESMO Immuno-Oncology Congress | | | |
| 2018, December 10 8:00 a.m. | NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at ESMO immuno-oncology congress on December 13-16, 2018 | | | |
| 2018, December 03 0:01 a.m. | NOXXON announces convocation of an extra-ordinary general meeting of shareholders | | | |
| 2018, November 21 8:00 a.m. | NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer | | | |
| 2018, November 16 8:00 a.m. | NOXXON announces EUR 6.2 million equity capital raise including US$ 5 million from US family office - Acuitas Capital, LLC | | | |
| 2018, October 26 8:00 a.m. | NOXXON to present top-line efficacy data from NOX-A12 / Keytruda combination trial in December as planned at ESMO Immuno-Oncology Conference | | | |
| 2018, October 23 6:00 p.m. | NOXXON to attend European investor and partnering conferences in November 2018 | | | |
| 2018, October 16 8:00 a.m. | NOXXON to attend the ESMO 2018 congress in Munich | | ||
| 2018, October 11 8:00 a.m. | NOXXON publishes interim 2018 results | | | |
| 2018, October 02 6:00 p.m. | NOXXON presents top-line data from NOX-A12 monotherapy part of ongoing metastatic colorectal and pancreatic cancer trial | | | |
| 2018, September 19 6:00 p.m. | NOXXON announces listing of convertible bonds and additional investment | | | |
| 2018, September 19 8:00 a.m. | NOXXON to present clinical trial data at Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 'Translating Science into Survival' | | | |
| 2018, September 03 8:00 a.m. | NOXXON announces completion of patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial | | | |
| 2018, August 14 8:00 a.m. | NOXXON raises additional funds via ODIRNANE bonds and extends timing to cancel investor's unilateral right to invest | | | |
| 2018, August 08 6:00 p.m. | NOXXON to host Key Opinion Leader event on novel treatment approaches for glioblastoma on September 4th, 2018 | | | |
| 2018, August 01 8:00 a.m. | NOXXON announces that it has secured additional financing | | | |
| 2018, July 16 6:00 p.m. | NOXXON announces amendment to loan agreements | | | |
| 2018, July 13 6:00 p.m. | Half-yearly report on the liquidity contract with invest securities | | | |
| 2018, July 03 8:00 a.m. | NOXXON issues tranche of ODIRNANE bonds | | | |
| 2018, June 28 8:00 p.m. | NOXXON provides update on patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial | | | |
| 2018, June 22 8:00 a.m. | Results of NOXXON annual general shareholders meeting | | | |
| 2018, June 15 8:00 a.m. | NOXXON announces that it has secured additional financing | | | |
| 2018, June 06 6:00 p.m. | NOXXON issues seventh tranche of ODIRNANE bonds | | | |
| 2018, May 29 8:00 a.m. | NOXXON provides clinical update prior to American Society of Clinical Oncology (ASCO) annual conference | | | |
| 2018, May 18 6:00 p.m. | NOXXON announces convocation of the annual general meeting of shareholders | | | |
| 2018, May 15 6:00 p.m. | NOXXON to present clinical trial update at BioEquity Europe | | | |
| 2018, April 30 9:00 p.m. | NOXXON PHARMA N.V. reports 2017 financial results | | | |
| 2018, April 26 8:00 a.m. | NOXXON publishes results of extraordinary shareholders meeting | | | |
| 2018, April 10 8:00 a.m. | NOXXON announces initiation of analyst coverage by Aurgalys | | | |
| 2018, March 22 9:00 p.m. | NOXXON announces convocation of an extra-ordinary general meeting of shareholders | | | |
| 2018, March 13 8:00 a.m. | NOXXON renegotiates ODIRNANE BSA financing agreement to remove unilateral option for investor to subscribe for tranches and to cancel existing warrents | | | |
| 2018, January 31 6.00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2018, January 23 8:00 a.m. | NOXXON issues fourth tranche of ODIRNANE bonds | | | |
| 2017, November 22 | NOXXON announces its participation in three European investor conferences in November and December 2017 | | | |
| 2017, November 21 | NOXXON issues third tranche of ODIRNANE bonds | | | |
| 2017, October 30 | NOXXON releases interim 2017 results | | | |
| 2017, October 11 | NOXXON Pharma réaffirme son éligibilité au PEA-PME pour 2017/2018 (French only) | | ||
| 2017, October 03 | NOXXON Publishes Preclinical Proof-Of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors | | | |
| 2017, September 29 | NOXXON Supervisory Board elects experienced US and EU biotech veteran Don deBethizy chairman | | | |
| 2017, September 28 | NOXXON provides update on ongoing phase 1/2 clinical trial with lead program NOX-A12 | | | |
| 2017, September 26 | NOXXON announces its participation in two french investor conferences in October 2017 | | | |
| 2017, September 19 | NOXXON issues second tranche of ODIRNANE bonds | | | |
| 2017, August 25 | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2017, July 18 | NOXXON issues first tranche of ODIRNANE bonds | | | |
| 2017, July 11 | NOXXON Pharma announces prospectus publication and share transfer to the public offering compartment of the EuroNext Growth market | | | |
| 2017, July 04 | NOXXON announces first patients treated in phase I/II clinical trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer | | | |
| 2017, June 29 | Results of NOXXON Annual General Meeting | | | |
| 2017, June 07 | NOXXON publishes Annual General Meeting Documents | | | |
| 2017, May 26 | NOXXON announces record date and date of annual general meeting | | | |
| 2017, May 16 | NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/Keytruda phase 1/2 combination trial | | | |
| 2017, May 02 | NOXXON PHARMA SECURES A PRIVATE PLACEMENT OF EUR 1 MILLION AND ADDITIONAL FINANCING OF UP TO EUR 10 MILLION THROUGH CONVERTIBLE NOTES WITH SHARE SUBSCRIPTION WARRANTS ATTACHED TO FINANCE FURTHER CLINICAL DEVELOPMENT OF NOX-A12 | | | |
| 2017, April 30 | NOXXON Pharma N.V. reports 2016 financial results and announces advanced discussions regarding a convertible bond financing | | | |
| 2017, February 10 | NOXXON Pharma announces experienced industry cancer clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO | | | |
| 2017, January 06 | Half-yearly report on the liquidity contract with INVEST securities | | | |
| 2017, January 04 | NOXXON PHARMA licenses and assigns preclinical Spiegelmer programs to APTARION | | | |
| 2016, December 15 | NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (pembrolizumab) in pancreatic and colorectal cancer | | | |
| 2016, December 05 | NOXXON Pharma announces new preclinical data showing synergy of lead compound NOX-A12 with natural killer (NK) Cell mediated therapies | | | |
| 2016, October 31 | NOXXON releases its interim 2016 results | | | |
| 2016, October 24 | NOXXON Pharma announces the implementation of a liquidity contract with invest securities | | | |
| 2016, October 10 | NOXXON Pharma demonstrates synergies between NOX-A12 and therapies working through T cells or NK cells | | | |
| 2016, September 28 | NOXXON Pharma NV lists its shares on Alternext Paris | | | |
| 2016, January 20 | NOXXON Pharma hosts key opinion leader symposium | | ||
| 2015, July 14 | NOXXON appoints Aram Mangasarian as CEO | | | |
| 2015, May 29 | First Data from NOXXONs NOX-H94 (Lexaptepid Pegol) Clinical Trial in ESA-Hyporesponsive Dialysis Patients Reported at ERA-EDTA Conference | | | |
| 2015, April 23 | Nature Communications Publications on the First X-ray Crystal Structures of Spiegelmers Bound to Protein Targets | | | |
| 2014, December 10 | New Addition to NOXXON Supervisory Board Brings Significant US Public Market Expertise | | | |
| 2014, December 05 | Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference | | | |
| 2014, September 26 | Cell Reports Publication on the Mechanism of Action of NOXXONs Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models | | | |
| 2014, September 23 | NOXXON Spiegelmer receives FDA Orphan Drug Designation for Glioblastoma Treatment | | | |
| 2014, September 18 | NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer | | | |
| 2014, September 04 | Two Presentations at International Conferences of Preclinical Data on NOXXON's anti-C5a Spiegelmer, a Potential Drug in Pneumococcal Pneumonia-Induced Sepsis | | | |
| 2014, July 31 | NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) in Dialysis Patients with EPO-hyporesponsive Anemia | | | |
| 2014, June 13 | NOXXON presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients | | | |
| 2014, June 02 | NOXXONs Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference | | | |
| 2014, April 08 | Anti-Hepcidin Spiegelmer Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study | | | |
| 2014, April 04 | NOXXON presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study | | | |
| 2013, December 09 | NOXXON presenting at ASH 2013 | | | |
| 2013, July 24 | NOXXON Pharma Completes Patient Recruitment for Phase IIa Study in Diabetic Nephropathy | | | |
| 2012, December 04 | NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94 | | | |
| 2012, September 26 | NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 in Second Oncology Indication: Multiple Myeloma | | | |
| 2012, July 11 | NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia | | | |
| 2012, June 19 | NOXXON Initiates Phase IIa of Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy | | | |
| 2012, April 4 | NOXXONs NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model | | | |
| 2012, January 6 | NOXXON to Present at 30th Annual J.P. Morgan Healthcare Conference | | | |
| 2011, December 12 | NOXXONs SDF-1 inhibitor NOX-A12 completes Phase I | | | |
| 2011, September 06 | NOXXON initiates Phase I of NOX-H94 for Anemia of Chronic Disease | | | |
| 2011, February 03 | NOXXON Expands Management Team | | | |
| 2010, October 12 | NOXXON Confirms Total Capital Raise of €35m | | | |
| 2010, September 22 | NOXXON initiates multiple dose phase I clinical trial of SDF-1 inhibitor NOX-A12 | | | |
| 2010, July 7 | NOXXON to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36 | | | |
| 2010, June 28 | NOXXON Pharma AG announces management changes | | | |
| 2010, May 27 | NOXXON Pharma AG raises €33 million in Series D Round | | | |
| 2010, May 18 | NOXXON Pharma AG appoints Dr. Aram Mangasarian as Chief Business Officer | | | |
| 2010, May 3 | NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A 12 | | | |
| 2009, December 3 | NOXXON Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company | | | |
| 2009, November 2 | NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12 | | | |
| 2009, October 12 | NOXXON announces excellent preliminary phase I trial results for Spiegelmer NOX-E36 | | | |
| 2009, September 3 | NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12 | | | |
| 2009, June 8 | NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer | | | |
| 2008, July 8 | NOXXON Pharma announces appointment of Lawrence E. Posner to its Board of Directors | | ||
| 2008, June 11 | NOXXON Pharma AG Announces Licensing and Discovery Collaboration with Eli Lilly ... | | | |
| 2008, April 7 | NOXXON Receives Research Grant from the Federal Ministry of Education and Research | | ||
| 2008, January 7 | NOXXON Pharma AG appoints Dr. Frank Morich as CEO | | ||
| 2007, November 9 | NOXXON announces alliance with Roche | | ||
| 2007, June 8 | NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board | | ||
| 2007, May 3 | NOXXON Pharma closes Series C Round at Euro 37 million | | ||
| 2007, February 9 | NOXXON Pharma AG to present at Bio CEO & Investor Conference 2007 in New York | | ||
| 2006, November 3 | NOXXON Pharma AG to present at Bio-Europe in Duesseldorf, Germany | | ||
| 2006, November 3 | NOXXON Pharma AG to present at Rodman & Renshaw 8th Annual Healthcare Conference | | ||
| 2006, October 4 | NOXXON Pharma AG to present at Sachs Associates 6th Annual Biotech in Europe... | | ||
| 2006, May 12 | NOXXON Pharma AG to present at the Rodman & Renshaw 3rd Annual Global Healthcare... | | ||
| 2006, May 10 | Change of management at NOXXON Pharma AG | | ||
| 2006, March 23 | NOXXON Pharma AG announces global strategic alliance with Pfizer. NOX-B11... | | ||
| 2006, March 15 | NOXXON Pharma AG announces publication of positive animal data with its vasopressin | | ||
| 2006, March 13 | NOXXON Pharma AG to present at Sachs Associates’ 5th Annual North America Forum... | | ||
| 2006, February 13 | NOXXON Pharma AG to present at Bio CEO & Investor Conference 2006 in New York | | ||